Search Results
53 Results Found for “chronic kidney disease”
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide.1 High systolic blood pressure (SBP) remains one of the top risk factors for CVD burden globally.2 Despite being a modifiable risk factor, hypertension (HTN) remains largely undiagnosed and ...
The first dedicated ESC Guidelines on the management of cardiovascular disease and chronic kidney disease recommend kidney function and urine albumin testing in all patients with cardiovascular disease, with an emphasis on identifying CKD early and initiating effective treatment without delay.
Dr Arasi Maran explores practical strategies for integrating lifestyle interventions into the management of complex coronary artery disease, including how to prioritise modifiable risk factors, communicate recommendations effectively and support sustained behaviour change. She also discusses the role of imaging, reliable health information and patient-centred approaches to improving adherence.
New clinical guidelines, late-breaking trials, artificial intelligence, and an increasing focus on cardiometabolic and precision medicine are set to shape discussions at ESC Congress 2026 in Munich.
The American Heart Association (AHA), American College of Cardiology (ACC), American Diabetes Association (ADA) and American Society of Nephrology (ASN) have issued a new joint clinical practice guideline for the prevention, detection, evaluation and management of cardiovascular-kidney-metabolic (CKM) syndrome.
Hypertension is the leading modifiable risk factor for global cardiovascular disease, responsible for an estimated 10.8 million deaths and more than 200 million disability-adjusted life years annually.1 Despite the availability of effective pharmacological and lifestyle interventions, prevalence continues to rise, particularly in ...
Sudden cardiac arrest (SCA) in young adults (typically defined as individuals younger than 40 years) has emerged as an important yet under-recognized public health concern. Recent estimates suggest an incidence of approximately 1–4 cases per 100,000 person-years, underscoring the clinical and epidemiological relevance ...
Hypertension affects over 1.4 billion adults worldwide and remains the leading modifiable risk factor for global cardiovascular (CV) morbidity and mortality. It is responsible for an estimated 10.8 million deaths annually and contributes significantly to the global burden of ischaemic heart disease, ...
Hypertension has been associated with increased cardiovascular morbidity and mortality, as well as with overall elevated all-cause mortality.1 Prevalence increases with age, affecting 28.5% of US individuals aged 20–44 years, 58.6% of those aged 45–64 years and 76.5% of those aged 65 years and older.2 In ...
Heart failure (HF) is a global health burden, with a 2019 prevalence of 711.90 per 100,000 population, totalling 56.19 million cases and 5.05 million years lived with disability, despite only modest declines since 1990.1 Recent years have shown an uptick in prevalence, driven by ageing populations ...
Cardiovascular disease (CVD) is one of the major causes of morbidity and mortality throughout the world.1,2 While traditional risk factors are managed intensively, many individuals continue to have considerable residual risk, and emerging factors such as inflammatory mediators are being ...
In this episode, Nicky speaks with Prof. Georgina Ellison-Hughes from King’s College London about the groundbreaking field of senolytics and their potential to advance the treatment of age-related diseases. From understanding the science behind cellular senescence to how senolytic drugs work and what early clinical trials reveal, this episode explores an exciting frontier in longevity medicine.
ObesityWeek® 2025 highlighted obesity as a chronic, multi-system disease that links cardiovascular, renal, and metabolic health. New data from clinical trials showcased therapies improving weight, blood pressure, and inflammation, signalling a shift toward integrated care where obesity management becomes central to cardiovascular risk reduction.
Despite advancements in mortality rates from cardiovascular disease (CVD) over the last 50 years, it remains the leading cause of death for women and the third leading cause for women aged 18 to 44.1 A 2011 report from the American Heart Association (AHA) starkly ...
In this Q&A, Dr Kheirkhah shares how her winding academic journey led her to a passion for atherosclerosis, the impact of collaborative mentorship, and her excitement for how big data, multi-omics and machine learning are reshaping cardiovascular risk prediction and disease prevention.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an inexorably progressive and ultimately fatal cardiomyopathy characterized by the deposition of misfolded transthyretin (TTR) in the form of amyloid fibrils within the myocardium.1 Transthyretin amyloid (ATTR) fibrils are insoluble protease-resistant beta-pleated sheets that are ...
Tricuspid regurgitation (TR) is a frequent finding on echocardiography, with detection rates reaching up to 86% across the different ranges of severity, with moderate or greater TR being reported in at least 6–8% of patients.1–3 The prevalence of TR increases with age, ...
Cardiovascular diseases are the most common cause of mortality and morbidity in adults worldwide.1 Coronary angiography (CAG) is the gold standard method for evaluating atherosclerotic coronary artery disease (CAD).2 It is conventionally performed via the trans-femoral (TF) route. Recently, however, ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
